1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Pennsylvania >
  6. Adare Pharma Solutions Acquires Egalet - Parvulet Technology Platform

M&A Deal Summary

Adare Pharma Solutions Acquires Egalet - Parvulet Technology Platform

On April 15, 2019, Adare Pharma Solutions acquired medical products company Egalet - Parvulet Technology Platform from Zyla Life Sciences

Acquisition Highlights
  • This is Adare Pharma Solutions’ 1st transaction in the Medical Products sector.
  • This is Adare Pharma Solutions’ 1st transaction in the United States.
  • This is Adare Pharma Solutions’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2019-04-15
Target Egalet - Parvulet Technology Platform
Sector Medical Products
Buyer(s) Adare Pharma Solutions
Sellers(s) Zyla Life Sciences
Deal Type Divestiture

Target

Egalet - Parvulet Technology Platform

Wayne, Pennsylvania, United States
Egalet Corp. - Parvulet Technology Platform is protected by several patents granted in the United States, Canada, and Europe with patent life ranging from five to 10 years. Using commonly used pharmaceutical excipients, the technology enables single-dose formulation of taste-masked, easy-to-swallow oral medications with a soft food like texture for pediatric and geriatric populations (including those with dysphagia). One of the unique features of the technology is its ability to enable high dose regimens that may not be feasible by other means.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Adare Pharma Solutions

Lawrenceville, New Jersey, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Adare Pharma Solutions provides enhanced medicines, creating new possibilities for improved patient health. Adare Pharma Solutions has solved complex formulation, manufacturing, and commercialization challenges, resulting in transformational medicines that deliver value to all its stakeholders. The company has a global presence with R&D, manufacturing, and commercial operations in the Unites States, Europe, and Canada. Adare Pharma Solutions was founded in 2015 and is based in Lawrenceville, New Jersey.

DEAL STATS #
Overall 1 of 3
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 2
Country: United States M&A 1 of 3
Year: 2019 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-04 Orbis Biosciences

Lenexa, Kansas, United States

Orbis Biosciences, Inc. is a pharmaceutical manufacturing technology company focused on licensing its technology to companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging Orbis’ novel Precision Particle Fabrication® technology platforms: Optimµm® precision encapsulation for oral delivery, StratµmTM precision encapsulation for injectable delivery, and the Unisun® platform for enabling sustained-release otic therapies. Orbis Biosciences is based in Lenexa, Kansas.

Buy -

Seller(S) 1

SELLER

Zyla Life Sciences

Wayne, Pennsylvania, United States
Category Company
Founded 2010
Sector Life Science
Employees130
Revenue 30M USD (2018)
DESCRIPTION

Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. Zyla Life Sciences portfolio includes six products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only - CII. Zyla Life Sciences was founded in 2010 and is based in Wayne, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-31 Iroko Pharmaceuticals - Four Non-Narcotic Pain Products

Philadelphia, Pennsylvania, United States

Iroko Pharmaceuticals LLC - Four Non-Narcotic Pain Products comprises low-dose SoluMatrix non-steroidal anti-inflammatory products, VIVLODEX (meloxicam), TIVORBEX (indomethacin), and ZORVOLEX (diclofenac), as well as INDOCIN® (indomethacin) oral suspension and suppositories or capsules and SoluMatrix naproxen, a phase 2 products.

Buy -
Mergr

Solution for

Product

Company

Legal